ArticleAMB Express2016
Angiogenic inhibitors delivered by the type III secretion system of tumor-targeting Salmonella typhimurium safely shrink tumors in mice.
Article in AMB Express, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Medium dependent factors govern the functionality of engineered type III secretion systems.Journal of biological engineering · 2025Article
- Engineering non-pathogenic bacteria for auto-transporter-driven secretion of functional interferon.Gut microbes · 2025Article
- Engineered bacteria: Strategies and applications in cancer immunotherapy.Fundamental research · 2025Review
- Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation.NPJ biofilms and microbiomes · 2025Review
- Bacterial therapies at the interface of synthetic biology and nanomedicine.Nature reviews bioengineering · 2024Article
- Gut microbiota and its therapeutic implications in tumor microenvironment interactions.Frontiers in microbiology · 2024Review
- Engineered bacteria as drug delivery vehicles: Principles and prospects.Engineering microbiology · 2022Review
- Recombinant AttenuatedCancers · 2022Review
- Bacterial-Based Cancer Therapy (BBCT): Recent Advances, Current Challenges, and Future Prospects for Cancer Immunotherapy.Vaccines · 2021Review
- Use ofFrontiers in oncology · 2021Review
- Microbes as Medicines: Harnessing the Power of Bacteria in Advancing Cancer Treatment.International journal of molecular sciences · 2020Review
- Article
- Bacteria-cancer interactions: bacteria-based cancer therapy.Experimental & molecular medicine · 2019Review
- Design of Outer Membrane Vesicles as Cancer Vaccines: A New Toolkit for Cancer Therapy.Cancers · 2019Review
- Engineering advanced cancer therapies with synthetic biology.Nature reviews. Cancer · 2019Review
- Rationale redesign of type III secretion systems: toward the development of non-pathogenic E. coli for in vivo delivery of therapeutic payloads.Current opinion in microbiology · 2018Review
- Local application of bacteria improves safety of Salmonella -mediated tumor therapy and retains advantages of systemic infection.Oncotarget · 2017Article
- Intracellular delivery of biologic therapeutics by bacterial secretion systems.Expert reviews in molecular medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite of a growing number of bacterial species that apparently exhibit intrinsic tumor-targeting properties, no bacterium is able to inhibit tumor growth completely in the immunocompetent hosts, due to its poor dissemination inside the tumors. Oxygen and inflammatory reaction form two barriers and restrain the spread of the bacteria inside the tumors. Here, we engineered a Salmonella typhimurium strain named ST8 which is safe and has limited ability to spread beyond the anaerobic regions of tumors. When injected systemically to tumor-bearing immunocompetent mice, ST8 accumulated in tumors at levels at least 100-fold greater than parental obligate anaerobic strain ST4. ST8/pSEndo harboring therapeutic plasmids encoding Endostatin fused with a secreted protein SopA could target vasculature at the tumor periphery, can stably maintain and safely deliver a therapeutic vector, release angiogenic inhibitors through a type III secretion system (T3SS) to interfere with the pro-angiogenic action of growth factors in tumors. Mice with murine CT26 colon cancer that had been injected with ST8/pSEndo showed efficient tumor suppression by inducing more severe necrosis and inhibiting blooding vessel density within tumors. Our findings provide a therapeutic platform for indirectly acting therapeutic strategies such as anti-angiogenesis and immune therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.